Compare TJX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TJX | VRTX |
|---|---|---|
| Founded | 1962 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.6B | 128.8B |
| IPO Year | 1994 | 2006 |
| Metric | TJX | VRTX |
|---|---|---|
| Price | $131.73 | $523.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 29 |
| Target Price | $169.00 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 6.1M | 876.4K |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 14.32 | ★ 836.54 |
| EPS | 2.55 | ★ 8.33 |
| Revenue | ★ $29,078,407,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.75 | $10.79 |
| Revenue Next Year | $5.81 | $10.47 |
| P/E Ratio | ★ $51.09 | $63.35 |
| Revenue Growth | 6.04 | ★ 46.20 |
| 52 Week Low | $122.81 | $392.82 |
| 52 Week High | $170.00 | $560.25 |
| Indicator | TJX | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 50.98 |
| Support Level | $122.81 | $423.93 |
| Resistance Level | $162.20 | $533.67 |
| Average True Range (ATR) | 2.73 | 11.06 |
| MACD | 1.42 | -0.28 |
| Stochastic Oscillator | 94.77 | 79.50 |
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.